

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6125828

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT		
CONVEYING PARTY DATA			
Name			Execution Date
BELLUS HEALTH INC.			05/25/2012
RECEIVING PARTY DATA			
Name:	BHI LIMITED PARTNERSHIP		
Street Address:	275 ARMAND-FRAPPIER BOULEVARD		
Internal Address:	LAVAL		
City:	QUEBEC		
State/Country:	CANADA		
Postal Code:	H7V 4A7		
PROPERTY NUMBERS Total: 1			
Property Type	Number		
Application Number:	16857520		
CORRESPONDENCE DATA			
Fax Number:	(202)842-7899		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	617 937-2473		
Email:	lromano@cooley.com		
Correspondent Name:	THOMAS J. PAXTON		
Address Line 1:	COOLEY LLP		
Address Line 2:	1299 PENNSYLVANIA AVENUE NW		
Address Line 4:	WASHINGTON, D.C. 20004		
ATTORNEY DOCKET NUMBER:	ALZH-001/06US		
NAME OF SUBMITTER:	THOMAS J. PAXTON		
SIGNATURE:	/Thomas J. Paxton/		
DATE SIGNED:	05/28/2020		
Total Attachments: 3			
source=ALZH-00106US-Assignment Bellus Health Inc to BHI Limited#page1.tif			
source=ALZH-00106US-Assignment Bellus Health Inc to BHI Limited#page2.tif			
source=ALZH-00106US-Assignment Bellus Health Inc to BHI Limited#page3.tif			

ASSIGNMENT

BELLUS HEALTH INC., a Corporation organized under the Canada Business Corporations Act, having its principal place of business at 275 Armand-Frappier Boulevard, Laval, Québec, H7V 4A7, Canada, (the "Assignor") in consideration of valuable consideration paid to it by:

BHI LIMITED PARTNERSHIP

a limited partnership constituted pursuant to the laws of the Province of Québec, Canada, having its principal place of business at 275 Armand-Frappier Boulevard, Laval, Québec, H7V 4A7, Canada, the receipt of which is hereby acknowledged, does hereby sell, assign and transfer unto said

BHI LIMITED PARTNERSHIP

its successors and assigns (collectively the "Assignee"), the entire interest for Canada, the United States of America, and all foreign countries in certain invention(s) or improvement(s) described in the Patents and Applications listed in Schedule A, including all rights of priority under the International Convention for the Protection of Industrial Property, in any Patent Office, and in all Letters Patent in any country which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuation, continuation-in-part, reexamination, reissue, national phase, regional phase, validation, or other applications or patents based in whole or in part thereon, the same to be held and enjoyed by the Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted or extended, as fully and entirely as the same would have been held and enjoyed by the Assignor had this assignment not been made. And the Assignor agrees, for itself and its successors and assigns, with the Assignee and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in Canada, the United States and in all other countries to the Assignee, with specifications and claims in such form as shall be approved by the counsel of said Assignee and to vest and confirm in the Assignee the legal title to all such Patents and Applications.

And the Assignor does hereby authorize and request the Commissioner of Patents and Trademarks of Canada, the United States and all other Patent Offices to issue such Letters Patent as shall be granted upon said application or applications based thereon to the Assignee.

On behalf of BELLUS HEALTH INC.:

Date: May 25, 2012


Witness:

Date: May 25, 2012


Date: May 25, 2012

Witness:


Date: May 25, 2012




Name: Roberto Bellini
Title: President



Name: Nicole Picher



Name: François Desjardins
Title: Vice-President, Finance



Name: NICOLE TIMBRE

On behalf of 8103968 CANADA INC., in its capacity as general partner of BHI Limited Partnership:


Date: May 25, 2012


Witness:

Date: May 25, 2012



Name: Roberto Bellini
Title: President





Name: NICOLE TIMBRE

SCHEDULE A

050 – Methods, Compounds, Compositions and Vehicles for Delivering 3-Amino-1-Propanesulfonic Acid

Country	Application No. (Publication No.)	Grant No.
U.S.A.	60/851,039	
U.S.A.	60/911,459	
U.S.A.	11/871,639	
PCT	PCT/IB2007/004704 (WO2006/019334)	
Australia	2007357451	
Brazil	PI 0717794-1	
Canada	2,666,246	
China	200780037964.1	
Eurasia	200970287	
Europe	07875176.5	
Hong Kong	10101380.4	
India	3005/DELNP/2009	
Israel	197852	
Japan	2009-531940	
Korea (South)	10-2009-7008847	
Mexico	MX/a/2009/003768	
New Zealand	576285	
Singapore	200902406-8	
Singapore	201107332-7	
South Africa	2009/03030	2009/03030